Jafri S M, Borzak S, Goldberger J, Gheorghiade M
Henry Ford Hospital, Detroit, MI 48202, USA.
Prog Cardiovasc Dis. 1998 Jul-Aug;41(1):65-70. doi: 10.1016/s0033-0620(98)80023-6.
The role of antiarrhythmic agents in the post-MI patients has been investigated for several years. Recently, clinical trials have assessed the effects of amiodarone in the post-MI population. The Basel Antiarrhythmic Study of Infarct Survival (BASIS) trial showed a reduction in total mortality, sudden death, and life-threatening ventricular arrhythmias with amiodarone therapy. The European Myocardial Infarct Amiodarone Trial (EMIAT) did not show a mortality benefit, but amiodarone was associated with fewer antiarrhythmic deaths. The Canadian Amiodarone Myocardial Infarction Trial (CAMIAT) showed no significant impact on mortality, but arrhythmia deaths and resuscitated cardiac deaths were reduced. Amiodarone therapy after MI should be reserved for the treatment of symptomatic or sustained ventricular arrhythmias. The current data do not support routine use of amiodarone in all patients after MI.
抗心律失常药物在心肌梗死（MI）后患者中的作用已被研究多年。最近，临床试验评估了胺碘酮在心肌梗死后人群中的效果。巴塞尔心肌梗死生存抗心律失常研究（BASIS）试验表明，胺碘酮治疗可降低总死亡率、心源性猝死和危及生命的室性心律失常。欧洲心肌梗死胺碘酮试验（EMIAT）未显示出死亡率获益，但胺碘酮与较少的抗心律失常药物相关死亡有关。加拿大胺碘酮心肌梗死试验（CAMIAT）显示对死亡率无显著影响，但心律失常死亡和复苏的心脏性死亡有所减少。心肌梗死后的胺碘酮治疗应仅用于有症状的或持续性室性心律失常的治疗。目前的数据不支持在所有心肌梗死后患者中常规使用胺碘酮。
